@ClassAct7576512@ShaykhSulaiman ? Reform UK - please stop posting such malicious comments. As one of the demonstrators said - please think before you act
Brilliant speech by Marcela Ferrada about #VEXAS at #EULAR2024
Key features to keep in mind ARE NOT gender and age of patients but ARE
🔴 unusual inflammatory features
🔴 elevated inflammatory markers
🔴 elevated MCV
🔴diagnosis is by genetic testing🔴
MP
Excellent talk (as usual) of @HelenLachmann in #EULAR2024 on TRAPS syndrome. She raised awaireness to be cautious in presence of R92Q variant in TNFRSF1A which may be associated more likely with SURF/USAID than prototypic TRAPS
The epi of Behcets in CPRD & linked HES in news at #EULAR2024
Increasing prevalence, incidence stable
Increased risk of BD in the presence of phenotypically linked MHC1 diseases
Median time to diagnosis shortest for Genital ulceration!
@devasitunayake@JohtChandan@Janetbirdope
Vast numbers of epidemiological papers basically say ‘this definitely isn’t in any way causal evidence, but here are some policy interventions we think are supported by this not-causal evidence’.
And I don’t think that’s very helpful.
Some thoughts: https://t.co/2gNXTQBB1t
Pleased to share our review in the @TheLancetRheum discussing current insights and future frontiers for inflammatory #myopathies. Full text and pictures accessible here! https://t.co/F3JHH5XJZM
#HappyNewYear2024
I decided to ask a chosen few their realistic personal hope for 2024
The few are those who I have a connection with whether it’s been recent or longstanding!
All are worth sharing
🧵
Gave my first talk on #Behçet this week!
Proud to highlight work of a former research trainee: Femoral vein wall thickness: A new diagnostic tool for #Behçet’s disease @drfatmaalibaz#vasculitis@HanerDireskenel https://t.co/oY034Q5OFB
✨ Phenomenal review of #Behcet’s by Dr. Seyahi #IRACON21
For Venous/Arterial Thrombosis
🎯 Immunesuppression is KEY! 👉 Anti-TNF 1st
🎯 Anticoag controversial but added if
👉 Low bleeding risk
👉 NO Pulmonary Artery aneurysm
👉 DOACs may be reasonable
📢 Hot of the press! Latest @Official_ASAS publication reiterates pivotal consensus on #axSpA nomenclature: "axSpA" as the universal term; "r-axSpA" preferred to "AS". Next steps: consistent adoption in educational materials, manuscripts, presentations, ICD-coding integration.